| 摘要 |
Described are compounds of formula (I) wherein G, R1 and R2 are defined as in the NZ Patent 336623 that exhibit activity as nitric oxide synthase (NOS) inhibitors, pharmaceutical compositions containing them and to their use in the treatment and prevention of central nervous system and other disorders such as migraine inflammatory diseases, stroke, acute and chronic pain, hypovolemic shock, traumatic shock, reperfusion injury, Crohn's disease, ulcerative colitis, septic shock, multiple sclerosis, AIDS associated dementia, neurodegenerative diseases, neuron toxicity, Alzheimer's disease, chemical dependencies and addictions, emesis, epilepsy, anxiety, psychosis, head trauma, adult respiratory distress syndrome (ARDS), morphine induced tolerance and withdrawal symptoms; inflammatory bowel disease, osteoarthritis, rheumatoid arthritis, ovulation, dilated cardiomyopathy, acute spinal cord injury, Huntington's disease, Parkinson's disease, glaucoma, macular degeneration, diabetic neuropathy, diabetic nephsopathy and cancer in a non-human mammal, (62) Divided out of 507373
|
